Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A Bridging to HSCT in r/r B-ALL
NCT05679687Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thiscart19a in acute lymphoblastic leukemia (ALL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Objective Response Rate at 4 weeks and Minimal Residual Disease Negativity at 4 weeks. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05679687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679687.